Advanced Biomedical Technologies (OTCMKTS:ABMT – Get Rating) and Cadre (NYSE:CDRE – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.

Insider & Institutional Ownership

34.1% of Cadre shares are owned by institutional investors. 34.1% of Advanced Biomedical Technologies shares are owned by company insiders. Comparatively, 52.9% of Cadre shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk and Volatility

Advanced Biomedical Technologies has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500. Comparatively, Cadre has a beta of 1.64, meaning that its stock price is 64% more volatile than the S&P 500.

Profitability

This table compares Advanced Biomedical Technologies and Cadre's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Advanced Biomedical Technologies and Cadre's gross revenue, earnings per share and valuation.

Cadre has higher revenue and earnings than Advanced Biomedical Technologies.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Advanced Biomedical Technologies and Cadre, as provided by MarketBeat.com.

Cadre has a consensus target price of $32.80, suggesting a potential upside of 38.05%. Given Cadre's higher probable upside, analysts clearly believe Cadre is more favorable than Advanced Biomedical Technologies.

Summary

Cadre beats Advanced Biomedical Technologies on 10 of the 11 factors compared between the two stocks.

About Advanced Biomedical Technologies

(Get Rating)

Advanced BioMedical Technologies, Inc. engages in the provision of medical and pain management tools. Its products include Electro-Acuscope 85P (Portable), Electro-Acuscope 80L, Neuroscope 230B, Electro-Myopulse 75L (Base Model), Electro-Myopulse 75F (Used in Fermi Lab Study), and Electro-Myopulse EMS 85P (Portable). The company was founded in 1984 and is headquartered in New York, NY.

About Cadre

(Get Rating)

Cadre Holdings, Inc. manufactures and distributes safety and survivability equipment that provides protection to users in hazardous or life-threatening situations in the United States and internationally. The company operates in two segments, Products and Distribution. It primarily provides body armor product, such as concealable, corrections, and tactical armor under the Safariland and Protech Tactical brands; survival suits, remotely operated vehicles, specialty tools, blast sensors, accessories, and vehicle blast attenuation seats for bomb safety technicians; bomb suits; duty gear, including belts and accessories; and other protective and law enforcement equipment comprising communications gear, forensic and investigation products, firearms cleaning solutions, and crowd control products. The company also offers third-party products, such as uniforms, optics, boots, firearms, and ammunition. It serves first responders, such as state and local law enforcement, fire and rescue, explosive ordnance disposal technicians, emergency medical technicians, fishing, and wildlife enforcement and departments of corrections, as well as federal agencies including the U.S. Department of State, U.S. Department of Defense, U.S. Department of Interior, U.S. Department of Justice, U.S. Department of Homeland Security, U.S. Department of Corrections, and various foreign government agencies. The company was founded in 1964 and is headquartered in Jacksonville, Florida.

Receive News & Ratings for Advanced Biomedical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanced Biomedical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.